SMAD9

SMAD9 (also SMAD8) is the least characterized R-SMAD, dedicated to BMP receptor signaling downstream of ALK1, ALK2, ALK3 and ALK6. Upon phosphorylation at its C-terminal SSXS motif, SMAD9 partners with SMAD4 to regulate transcription, with prominent roles in vascular and cardiac development. The best-established physiology of SMAD9 lies in the pulmonary circulation: in pulmonary artery endothelial cells, BMP9/BMP10-ALK1-SMAD9 signaling maintains quiescent endothelial phenotype, and loss-of-function SMAD9 mutations are an established genetic cause of pulmonary arterial hypertension (PAH), contributing around 1-3% of familial and idiopathic cases, sharing the pathway defect with BMPR2 and ACVRL1 mutations. SMAD9 mutation carriers develop endothelial apoptosis and obliterative vascular remodeling typical of PAH. Developmentally, Smad9-null mice display defects in embryonic angiogenesis, cardiac outflow tract and gastrointestinal patterning. SMAD9 signaling also participates in osteoblast differentiation and bone formation, and has been implicated in the tumor microenvironment response to BMPs, illustrating its niche in endothelial and skeletal biology.